Mastitis Market: Global Industry Analysis and Forecast (2024-2030)

  • Mastitis Market size was valued at USD 1.52 Bn. in 2023 and the Mastitis revenue is expected to grow at a CAGR of 5.8% from 2024 to 2030, reaching nearly USD 2.26 Bn. by 2030.

  • Format : PDF | Report ID : SMR_2101

Mastitis Market Overview:      

Mastitis is a condition where there is inflammation in breast tissue, which can sometimes be accompanied by an infection. While mastitis mostly affects women who are breastfeeding, it can also occur in women who are not breastfeeding and even in men. Breast inflammation can present as pain, swelling, warmth, and redness or fever and chills may occur in a patient. It is more prevalent at one to three days following childbirth but can also affect women who have not recently given birth as well as those who have reached menopause. Mastitis is majorly caused by blocked milk ducts, Bacteria infections (among others) in the breasts.   

 

Based on the data provided to us by Nestle Nutrition Institution, we estimate that up to 30% of all breastfeeding women develop Lactation Mastitis, the rates varying across populations; it may be as low as 2% or as high as 10%. Around 0.1–3% of them end up having puss mastitis.

 

The Mastitis Market report provides a detailed analysis of the strong competition, challenges and dominant sectors in the market. The key findings of the report include market size and forecasts period with current environmental and other developments that affect the Market. The Mastitis Market is segmented into type, Treatment and end-user which is presented with the help of graphs and figures for a better understanding of the fastest-growing segments. The report used both quantitative and qualitative methods for the analysis of the industry. The market size and estimations along with the growth rate are covered in the report. The bottom-up approach was used for market estimations which were validated by various segments.

Mastitis Market

 

To get more Insights: Request Free Sample Report

 

Mastitis Market Dynamics:  

Driving Forces behind the Booming Mastitis Market: Prevalence, Diagnostics, and Innovative Therapies

The major factors responsible for the market growth of bovine mastitis are: increased diseases incidence rate, a broad range of animal health products introduced into the market and technological advancements in drugs discovery and development. Significant growth is being witnessed by the mastitis market due to increasing prevalence, especially in lactating women, fuelling the demand for effective treatment options. Factors such as improper breastfeeding techniques and poor hygiene contribute to the rising cases of mastitis. People have started to notice mastitis disease due to the problems it may bring like breast abscesses or sepsis, this factor prompting early diagnosis to be prioritized more.

 

Growth in the market for this condition is also attributed to more sophisticated diagnostic methods based on ultrasound and blood analyses which enhance precision during diagnosis. Resistance has been spreading through bacterial populations to conventional antibiotics used in mastitis therapy, a factor contributing to both emergence of new therapies, development of better management protocols for mastitis control as well as environmental conservation measures that would mitigate antibiotic resistance risks.

 

Mastitis Market Challenges

Key Challenges Facing the Mastitis Market: Raw Material Volatility, Competition from Alternatives, High Capital Investments, and Environmental Concerns 

Several important problems make it hard for the mastitis market to grow. One of the biggest barriers is the growth of antibiotic resistance, where over time, the bacteria that cause mastitis have started to show resistance against common antibiotics available hence limited options for treatment. Poor awareness and lack of proper screening, particularly in developing areas lead to late diagnosis hence treating thus worsening the situation may develop complications. Besides, patients from underprivileged areas have an issue of high costs for treatment with advanced therapies and procedures as a diagnosis, which makes it difficult for them to get the best treatment.

 

The strict regulation criteria for new mastitis treatments approval also represent an obstacle as they delay the marketing of innovative therapies which in turn slows down the provision of modernized treatments. In distant locations, the largest problem of unskilled medics and inadequate healthcare centers is that they contribute to be late in diagnosing and dealing with mastitis in time. This only makes the problem of the market more complex.                    

 

Mastitis Market Segment Analysis:

By Type, Based on the type, the mastitis market can be segmented by type into bovine mastitis and human mastitis. Bovine mastitis, affecting dairy cattle, accounts for a significant share of the market, driven by the high prevalence of the condition in dairy herds and the substantial economic losses it causes for the dairy industry. Human mastitis, primarily affecting lactating women, is also a crucial segment, with increasing awareness and demand for effective treatment options contributing to its growth.

Mastitis Market1

Mastitis Market Regional Insight:

The mastitis market exhibits regional variations influenced by healthcare infrastructure, livestock management practices, and regulatory frameworks. In North America and Europe, stringent regulatory standards and advanced veterinary healthcare systems drive market growth, supported by high awareness among dairy farmers. Asia-Pacific, led by countries like India and China, experiences significant market expansion due to rising dairy production and increasing adoption of veterinary services. Latin America and the Middle East & Africa regions are emerging markets with growing investments in livestock health and dairy farming.

Mastitis Market2

Mastitis Market Competitive Landscape:

  • In June 2022: A new Biological Development Centre (BDC) at Boehringer Ingelheim's research development locations in Biberach, Germany, was revealed with a 230-million-euro investment. The BDC will be the company's first BDC.
  • In June 2021: Tavocept, an experimental novel medication developed by BioNumerik Pharmaceuticals, was approved by the Food and Drug Administration for use in both cancer and non-oncology purposes.

 

Mastitis Market Scope:

Mastitis Market

Market Size in 2023

USD 1.52 Bn.

Market Size in 2030

USD 2.26 Bn.

CAGR (2024-2030)

5.8 %

Historic Data

2018-2022

Base Year

2023

Forecast Period

2024-2030

   Segments

By Type 

  • Bovine

Contagious Mastitis

Environmental Mastitis

Opportunist Mastitis

  • Human

Non-Infectious Mastitis

Infectious Mastitis

By Treatment

  • Bovine

Antibiotics

Vaccines

  • Human

Pain Relievers

Antibiotics

By End User

             Veterinary Centers

             Hospital & Clinics

Regional Scope

North America- United States, Canada, and Mexico

Europe – UK, France, Germany, Italy, Spain, Sweden, Russia, and Rest of Europe

Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC

Middle East and Africa - South Africa, GCC, Egypt, Rest of the Middle East and Africa

South America – Brazil, Argentina, Rest of South America

 

Mastitis Market Key Players:

  1. Bayer AG
  2. Zoetis Inc.  
  3. Boehringer Ingelheim GmbH
  4. Merck Co. & Inc.
  5. Astellas Pharma Inc.
  6. Pfizer Inc.
  7. Novartis AG
  8. IDEXX Laboratories
  9. MSD Animal Health,  
  10. DeLaval International AB
  11. CEVA Santé Animale
  12. Vetoquinol
  13. HIPRA
  14. Kyoritsu Seiyaku Corporation
  15. Ceva Sante Animale
  16. Thermo Fisher Scientific
  17. Laboratorios SYVA
  18. IDEXX Laboratories
  19. Elanco Animal Health
  20. Hester Biosciences Limited


Frequently Asked Questions

Driving Forces behind the Booming Mastitis Market: Prevalence, Diagnostics, and Innovative Therapies.

1.    Mastitis Market: Research Methodology 
2.    Mastitis Market: Executive Summary
3.    Mastitis Market: Competitive Landscape
4.    Potential Areas for Investment

4.1. Stellar Competition Matrix
4.2. Competitive Landscape
4.3. Key Players Benchmarking
4.4. Market Structure
4.4.1.    Market Leaders 
4.4.2.    Market Followers
4.4.3.    Emerging Players

4.5. Consolidation of the Market
5.    Mastitis Market Import Export Landscape
5.1. Import Trends
5.2. Export Trends
5.3. Regulatory Compliance
5.4. Major Export Destinations
5.5. Import-Export Disparities
6.    Mastitis Market: Dynamics
6.1. Market Trends by Region
6.1.1.    North America
6.1.2.    Europe
6.1.3.    Asia Pacific
6.1.4.    Middle East and Africa
6.1.5.    South America

6.2. Market Drivers by Region
6.2.1.    North America
6.2.2.    Europe
6.2.3.    Asia Pacific
6.2.4.    Middle East and Africa
6.2.5.    South America

6.3. Market Restraints
6.4. Market Opportunities
6.5. Market Challenges
6.6. PORTER’s Five Forces Analysis
6.7. PESTLE Analysis
6.8. Strategies for New Entrants to Penetrate the Market
6.9. Regulatory Landscape by Region
6.9.1.    North America
6.9.2.    Europe
6.9.3.    Asia Pacific
6.9.4.    Middle East and Africa
6.9.5.    South America

7.    Mastitis Market Size and Forecast by Segments (by Value Units)
7.1. Mastitis Market Size and Forecast, by Type (2023-2030)
7.1.1.    Bovine
7.1.1.1.    Contagious Mastitis
7.1.1.2.    Environmental Mastitis
7.1.1.3.    Opportunist Mastitis
7.1.2.    Human
7.1.2.1.    Non-Infectious Mastitis
7.1.2.2.    Infectious Mastitis

7.2. Mastitis Market Size and Forecast, by Treatment(2023-2030)
7.2.1.    Bovine
7.2.1.1.    Antibiotics
7.2.1.2.    Vaccines
7.2.2.    Human
7.2.2.1.    Pain Relievers
7.2.2.2.    Antibiotics

7.3. Mastitis Market Size and Forecast, by End User (2023-2030)
7.3.1.    Veterinary Centers
7.3.2.    Hospital & Clinics

8.    North America Mastitis Market Size and Forecast (by Value Units)
8.1. North America Mastitis Market Size and Forecast, by Type (2023-2030)
8.1.1.    Bovine
8.1.1.1.    Contagious Mastitis
8.1.1.2.    Environmental Mastitis
8.1.1.3.    Opportunist Mastitis
8.1.2.    Human
8.1.2.1.    Non-Infectious Mastitis
8.1.2.2.    Infectious Mastitis

8.2. Mastitis Market Size and Forecast, by Treatment(2023-2030)
8.2.1.    Bovine
8.2.1.1.    Antibiotics
8.2.1.2.    Vaccines
8.2.2.    Human
8.2.2.1.    Pain Relievers
8.2.2.2.    Antibiotics

8.3. Mastitis Market Size and Forecast, by End User (2023-2030)
8.3.1.    Veterinary Centers
8.3.2.    Hospital & Clinics

8.4. North America Mastitis Market Size and Forecast, by Country (2023-2030)
8.4.1.    United States
8.4.2.    Canada
8.4.3.    Mexico

9.    Europe Mastitis Market Size and Forecast (by Value Units)
9.1. Europe Mastitis Market Size and Forecast, by Type (2023-2030)
9.1.1.    Bovine
9.1.1.1.    Contagious Mastitis
9.1.1.2.    Environmental Mastitis
9.1.1.3.    Opportunist Mastitis
9.1.2.    Human
9.1.2.1.    Non-Infectious Mastitis
9.1.2.2.    Infectious Mastitis

9.2. Mastitis Market Size and Forecast, by Treatment(2023-2030)
9.2.1.    Bovine
9.2.1.1.    Antibiotics
9.2.1.2.    Vaccines
9.2.2.    Human
9.2.2.1.    Pain Relievers
9.2.2.2.    Antibiotics

9.3. Mastitis Market Size and Forecast, by End User (2023-2030)
9.3.1.    Veterinary Centers
9.3.2.    Hospital & Clinics

9.4. Europe Mastitis Market Size and Forecast, by Country (2023-2030)
9.4.1.    UK
9.4.2.    France
9.4.3.    Germany
9.4.4.    Italy
9.4.5.    Spain
9.4.6.    Sweden
9.4.7.    Russia 
9.4.8.    Rest of Europe

10.    Asia Pacific Mastitis Market Size and Forecast (by Value Units)
10.1. Asia Pacific Mastitis Market Size and Forecast, by Type (2023-2030)
10.1.1.    Bovine
10.1.1.1.    Contagious Mastitis
10.1.1.2.    Environmental Mastitis
10.1.1.3.    Opportunist Mastitis
10.1.2.    Human
10.1.2.1.    Non-Infectious Mastitis
10.1.2.2.    Infectious Mastitis

10.2. Mastitis Market Size and Forecast, by Treatment(2023-2030)
10.2.1.    Bovine
10.2.1.1.    Antibiotics
10.2.1.2.    Vaccines
10.2.2.    Human
10.2.2.1.    Pain Relievers
10.2.2.2.    Antibiotics

10.3. Mastitis Market Size and Forecast, by End User (2023-2030)
10.3.1.    Veterinary Centers
10.3.2.    Hospital & Clinics

10.4. Asia Pacific Air Traffic Control (ATC) Communications Market Size and Forecast, by Country (2023-2030)
10.4.1.    China
10.4.2.    S Korea
10.4.3.    Japan
10.4.4.    India
10.4.5.    Australia
10.4.6.    Indonesia 
10.4.7.    Malaysia
10.4.8.    Vietnam
10.4.9.    Taiwan
10.4.10.    Bangladesh
10.4.11.    Pakistan
10.4.12.    Rest of Asia Pacific

11.    Middle East and Africa Mastitis Market Size and Forecast (by Value Units)
11.1. Middle East and Africa Mastitis Market Size and Forecast, by Type (2023-2030)
11.1.1.    Bovine
11.1.1.1.    Contagious Mastitis
11.1.1.2.    Environmental Mastitis
11.1.1.3.    Opportunist Mastitis
11.1.2.    Human
11.1.2.1.    Non-Infectious Mastitis
11.1.2.2.    Infectious Mastitis

11.2. Middle East and Africa Market Size and Forecast, by Treatment(2023-2030)
11.2.1.    Bovine
11.2.1.1.    Antibiotics
11.2.1.2.    Vaccines
11.2.2.    Human
11.2.2.1.    Pain Relievers
11.2.2.2.    Antibiotics

11.3. Mastitis Market Size and Forecast, by End User (2023-2030)
11.3.1.    Veterinary Centers
11.3.2.    Hospital & Clinics

11.4. Middle East and Africa Mastitis Market Size and Forecast, by Country (2023-2030)
11.4.1.    South Africa
11.4.2.    GCC
11.4.3.    Egypt
11.4.4.    Nigeria
11.4.5.    Rest of ME&A

12.    South America Mastitis Market Size and Forecast (by Value Units)
12.1. South America Mastitis Market Size and Forecast, by Type (2023-2030)
12.1.1.    Bovine
12.1.1.1.    Contagious Mastitis
12.1.1.2.    Environmental Mastitis
12.1.1.3.    Opportunist Mastitis
12.1.2.    Human
12.1.2.1.    Non-Infectious Mastitis
12.1.2.2.    Infectious Mastitis

12.2. South America Market Size and Forecast, by Treatment(2023-2030)
12.2.1.    Bovine
12.2.1.1.    Antibiotics
12.2.1.2.    Vaccines
12.2.1.3.    
12.2.2.    Human
12.2.2.1.    Pain Relievers
12.2.2.2.    Antibiotics

12.3. Mastitis Market Size and Forecast, by End User (2023-2030)
12.3.1.    Veterinary Centers
12.3.2.    Hospital & Clinics

12.4. South America Mastitis Market Size and Forecast, by Country (2023-2030)
12.4.1.    Brazil
12.4.2.    Argentina
12.4.3.    Rest of South America

13.    Company Profile: Key players
13.1. Bayer AG
13.1.1.1.    Company Overview
13.1.1.2.    Financial Overview
13.1.1.3.    Business Portfolio
13.1.1.4.    SWOT Analysis
13.1.1.5.    Business Strategy 
13.1.1.6.    Recent Developments

13.2. Zoetis Inc.  
13.3. Boehringer Ingelheim GmbH
13.4. Merck Co. & Inc.
13.5. Astellas Pharma Inc.
13.6. Pfizer Inc.
13.7. Novartis AG
13.8. IDEXX Laboratories
13.9. MSD Animal Health,  
13.10. DeLaval International AB
13.11. CEVA Santé Animale
13.12. Vetoquinol
13.13. HIPRA
13.14. Kyoritsu Seiyaku Corporation
13.15. Ceva Sante Animale
13.16. Thermo Fisher Scientific
13.17. Laboratorios SYVA
13.18. IDEXX Laboratories
13.19. Elanco Animal Health
13.20. Hester Biosciences Limited 
14.    Key Findings
15.    Industry Recommendation

Enquiry Before Buy


Request Sample PDF